Regulated Vascular Endothelial Growth Factor Signaling in Mice

improves the safety, effectiveness and quality of such medi-

prescribed in large doses. De-

poorly-de-

liver injury,5,6) gastrointestinal disorders,7) in

or other brain injuries.3) Among these changes, angiogenesis

occur (brain remodeling) in the chronic phase after ischemia

increases cerebral blood

separated into 3 sequential phases: acute (minutes to hours),

subacute (hours to days), and chronic (days to months).2)

Neurogenesis, gliosis/glial scar formation and angiogenesis

occur (brain remodeling) in the chronic phase after ischemia

or other brain injuries.3) Among these changes, angiogenesis

increases cerebral blood flow, and improves brain tissue recov-

ery as well as functional outcome.4)

Huanglian-Jie-Du-Tang (HJDT) is a traditional Chinese herbal formula which is widely used clinically. In this study, we investigated the effects of an aqueous (HJDTaq) and an ethanolic (HJDTet) extract of HJDT on chronic brain injury after focal cerebral ischemia in mice. The ischemia was induced by occlusion of the right middle cerebral artery for 30 min. HJDTaq (4 g/kg) and HJDTet (200, 400, 800 mg/kg) were orally administered for 21 d from day 7 before ischemia to day 14 after ischemia. The survival rate decreased to less than 50% at 35 d after ischemia. HJDTet at 400 mg/kg increased the survival rate. HJDTaq (4 g/kg) and HJDTet (400, 800 mg/kg) significantly attenuated the neurological dysfunction, brain atrophy and infarct volume after ischemia. There were few cells positive for CD31, hypoxia-inducible-factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and Flk-1 in the stem control. After ischemia, the number increased. HJDTaq (4 g/kg) and HJDTet (400 or 800 mg/kg) further increased the numbers of CD31, HIF-1α, VEGF and Flk-1-positive cells in the ischemic hemisphere. We conclude that HJDTaq and HJDTet have neuroprotective effects on chronic brain injury after focal cerebral ischemia and lead to accelerated angiogenesis by HIF-1α-regulated VEGF signaling.

Huanglian-Jie-Du-Tang (HJDT) is a traditional Chinese herbal formula which is widely used clinically. Ischemic brain injury can be separated into 3 sequential phases: acute (minutes to hours), subacute (hours to days), and chronic (days to months).2) Neurogenesis, gliosis/glial scar formation and angiogenesis occur (brain remodeling) in the chronic phase after ischemia or other brain injuries.3) Among these changes, angiogenesis increases cerebral blood flow, and improves brain tissue recovery as well as functional outcome.4)

Huanglian-Jie-Du-Tang (HJDT) is a traditional Chinese herbal formula composed of four herbs: Rhizoma Coptidis, Radix Scutellariae, Cortex Phellodendri and Fructus Gardeniae. It is widely used for alleviating the symptoms of liver injury;5) gastrointestinal disorders;6) inflammation;7) cardiovascular diseases;8) and multiple myeloma.9) Evidence shows that HJDT or its ingredient also protect against acute ischemic brain injury.10— 15) We showed previously that the aqueous extract of HJDT (HJDTaq) has neuroprotective effects on chronic brain injury after focal cerebral ischemia and lead to accelerated angiogenesis by HIF-1α-regulated VEGF signaling.

Key words aqueous extract; ethanolic extract; cerebral ischemia; angiogenesis; mouse

Cerebral ischemia and stroke are the leading causes of death in industrialized nations. Ischemic brain injury can be separated into 3 sequential phases: acute (minutes to hours), subacute (hours to days), and chronic (days to months). Neurogenesis, gliosis/glial scar formation and angiogenesis occur (brain remodeling) in the chronic phase after ischemia or other brain injuries. Among these changes, angiogenesis increases cerebral blood flow, and improves brain tissue recovery as well as functional outcome.

Huanglian-Jie-Du-Tang (HJDT) is a traditional Chinese herbal formula which is widely used clinically. Ischemic brain injury can be separated into 3 sequential phases: acute (minutes to hours), subacute (hours to days), and chronic (days to months). Neurogenesis, gliosis/glial scar formation and angiogenesis occur (brain remodeling) in the chronic phase after ischemia or other brain injuries. Among these changes, angiogenesis increases cerebral blood flow, and improves brain tissue recovery as well as functional outcome.

Huanglian-Jie-Du-Tang (HJDT) is a traditional Chinese herbal formula which is widely used clinically. Ischemic brain injury can be separated into 3 sequential phases: acute (minutes to hours), subacute (hours to days), and chronic (days to months). Neurogenesis, gliosis/glial scar formation and angiogenesis occur (brain remodeling) in the chronic phase after ischemia or other brain injuries. Among these changes, angiogenesis increases cerebral blood flow, and improves brain tissue recovery as well as functional outcome.

Huanglian-Jie-Du-Tang (HJDT) is a traditional Chinese herbal formula which is widely used clinically. Ischemic brain injury can be separated into 3 sequential phases: acute (minutes to hours), subacute (hours to days), and chronic (days to months). Neurogenesis, gliosis/glial scar formation and angiogenesis occur (brain remodeling) in the chronic phase after ischemia or other brain injuries. Among these changes, angiogenesis increases cerebral blood flow, and improves brain tissue recovery as well as functional outcome.

Huanglian-Jie-Du-Tang (HJDT) is a traditional Chinese herbal formula which is widely used clinically. Ischemic brain injury can be separated into 3 sequential phases: acute (minutes to hours), subacute (hours to days), and chronic (days to months). Neurogenesis, gliosis/glial scar formation and angiogenesis occur (brain remodeling) in the chronic phase after ischemia or other brain injuries. Among these changes, angiogenesis increases cerebral blood flow, and improves brain tissue recovery as well as functional outcome.

Huanglian-Jie-Du-Tang (HJDT) is a traditional Chinese herbal formula which is widely used clinically. Ischemic brain injury can be separated into 3 sequential phases: acute (minutes to hours), subacute (hours to days), and chronic (days to months). Neurogenesis, gliosis/glial scar formation and angiogenesis occur (brain remodeling) in the chronic phase after ischemia or other brain injuries. Among these changes, angiogenesis increases cerebral blood flow, and improves brain tissue recovery as well as functional outcome.

Huanglian-Jie-Du-Tang (HJDT) is a traditional Chinese herbal formula which is widely used clinically. Ischemic brain injury can be separated into 3 sequential phases: acute (minutes to hours), subacute (hours to days), and chronic (days to months). Neurogenesis, gliosis/glial scar formation and angiogenesis occur (brain remodeling) in the chronic phase after ischemia or other brain injuries. Among these changes, angiogenesis increases cerebral blood flow, and improves brain tissue recovery as well as functional outcome.

Huanglian-Jie-Du-Tang (HJDT) is a traditional Chinese herbal formula which is widely used clinically. Ischemic brain injury can be separated into 3 sequential phases: acute (minutes to hours), subacute (hours to days), and chronic (days to months). Neurogenesis, gliosis/glial scar formation and angiogenesis occur (brain remodeling) in the chronic phase after ischemia or other brain injuries. Among these changes, angiogenesis increases cerebral blood flow, and improves brain tissue recovery as well as functional outcome.

Huanglian-Jie-Du-Tang (HJDT) is a traditional Chinese herbal formula which is widely used clinically. Ischemic brain injury can be separated into 3 sequential phases: acute (minutes to hours), subacute (hours to days), and chronic (days to months). Neurogenesis, gliosis/glial scar formation and angiogenesis occur (brain remodeling) in the chronic phase after ischemia or other brain injuries. Among these changes, angiogenesis increases cerebral blood flow, and improves brain tissue recovery as well as functional outcome.

Huanglian-Jie-Du-Tang (HJDT) is a traditional Chinese herbal formula which is widely used clinically. Ischemic brain injury can be separated into 3 sequential phases: acute (minutes to hours), subacute (hours to days), and chronic (days to months). Neurogenesis, gliosis/glial scar formation and angiogenesis occur (brain remodeling) in the chronic phase after ischemia or other brain injuries. Among these changes, angiogenesis increases cerebral blood flow, and improves brain tissue recovery as well as functional outcome.

Huanglian-Jie-Du-Tang (HJDT) is a traditional Chinese herbal formula which is widely used clinically. Ischemic brain injury can be separated into 3 sequential phases: acute (minutes to hours), subacute (hours to days), and chronic (days to months). Neurogenesis, gliosis/glial scar formation and angiogenesis occur (brain remodeling) in the chronic phase after ischemia or other brain injuries. Among these changes, angiogenesis increases cerebral blood flow, and improves brain tissue recovery as well as functional outcome.

Huanglian-Jie-Du-Tang (HJDT) is a traditional Chinese herbal formula which is widely used clinically. Ischemic brain injury can be separated into 3 sequential phases: acute (minutes to hours), subacute (hours to days), and chronic (days to months). Neurogenesis, gliosis/glial scar formation and angiogenesis occur (brain remodeling) in the chronic phase after ischemia or other brain injuries. Among these changes, angiogenesis increases cerebral blood flow, and improves brain tissue recovery as well as functional outcome.
Fig. 1. Structures of Berberine (1), Baicalin (2), and Geniposide (3)

and geniposide protect against acute cerebral ischemia.\(^{19-21}\) Therefore, these three compounds (Fig. 1) were used for quantitative analysis of HJDTet. The content of berberine, baicalin, and geniposide in HJDTet was found to be 1.44%, 3.35%, and 2.12%, respectively. These may be main components of HJDT to protect against the chronic cerebral ischemia.

**Animals and Drug Treatment** Male Kunming mice, weighing 22—24 g, were purchased from Shanghai Slyke Laboratory Animal Corp. (Certificate No. SCXK 2007-0005, Shanghai, China) and acclimatized for 1 week before use. All experiments were carried out in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals. The animals were housed at a controlled temperature (22±1°C) and humidity 50±10%, under a 12/12 h light/dark cycle. They were allowed free access to food and water.

The mice were divided into 6 groups (n=163), each consisting of 25—31 mice. HJDTet (200 mg/kg, n=25; 400 mg/kg, n=27; 800 mg/kg, n=28) and HJDTaq (4 g/kg, n=25) were administered orally once a day for 21 d from day 7 before ischemia until day 14 after ischemia. The sham (n=27) and ischemia (n=31) controls were treated orally with 0.5% carboxymethyl cellulose solution.

**Transient Focal Cerebral Ischemia** Transient focal cerebral ischemia was induced by middle cerebral artery occlusion (MCAO) as described by Mao et al.\(^{22}\) After anesthesia with chloral hydrate (400 mg/kg), a 6—0 nylon monofilament suture, blunted at the tip and coated with 1% polyethylene glycol, was inserted into the internal carotid artery, and advanced approximately 10 mm distal to the carotid bifurcation to occlude the origin of the MCA. The suture was carefully withdrawn 30 min after MCAO. In sham-operated mice, the same procedure was done with the exception of inserting the intraluminal filament. The mice with intracranial haemorrhage were excluded.

**Neurological Deficit Score** The neurological deficit score was evaluated as described by Bederson et al.\(^{23}\): 0, no deficit; 1, failure to fully extend left forepaw; 2, circling to the left; 3, falling to the left; 4, no spontaneous walking with a depressed level of consciousness. Then, mice were scored on days 1, 3, and 7 in the first week after MCAO, and once every week thereafter.

**Inclined Board Test** An inclined board test was performed to assess balance and coordination based on modifications of a method described by Yonemori et al.\(^{24}\) Mice were placed on a board (25 cm×15 cm) covered by copper wire mesh (0.2 mm) after MCAO. Once the mouse had stabilized, the board was inclined from horizontal to vertical. The holding angle at which the animal fell from the board was recorded. The test was repeated three times and the average angle was calculated.

**Histopathological Examination** Mice were anesthetized after neurological evaluation at day 35 after MCAO and perfused transcardially with 4% paraformaldehyde after preflushing with ice-cold saline. Brains were removed, fixed with the same fixative for 24 h, and then stored in 30% sucrose in 0.1 M phosphate buffered saline at 4°C for 1—2 d. The brains were cut into 10 or 20-μm coronal sections on a cryomicrotome (CM1900, Leica, Germany) —2.0 mm from bregma. The 20-μm sections from the central region of the ischemic infarction were photographed by a digital camera (FinePix S6000 Zoom, Fuji Film, Japan). The infarct volume was measured using an image analyzer (MedBrain-2, Zhejiang University, Hangzhou, China) in sections stained with 1% toluidine blue (Sigma Chemical Co., St. Louis, MO, U.S.A.). Then, the 10-μm sections were used for histopathological examination and counting neuron densities in the hippocampal CA1 region, temporal cortex and striatum. The numbers of healthy-looking neurons (large cells with a pyramidal shape) in layers III—IV of the temporoparietal cortex, hippocampal CA1 region, and striatum were counted in sections stained with 1% toluidine blue.

**Immunohistochemical Evaluation** To assess post-ischemic angiogenesis, immunohistochemical procedures were performed using the polyclonal rabbit antibodies against CD31 (a marker of microvessels), hypoxia-inducible-factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and Flk-1. The 10-μm sections were treated with 0.3% H₂O₂ in methanol for 30 min, hydrated gradually to distilled water, and incubated for 2 h with 5% goat serum to block nonspecific immune reactions. Sections were then incubated overnight at 4°C with polyclonal rabbit anti-CD31, -HIF-1α, -VEGF and -Flk-1 antibodies (1:200, Wuhan Boster Biological Engineering Co., Wuhan, China). The next day, after washing, the sections were incubated with biotinylated goat anti-rabbit immunoglobulin G (1:200, Wuhan Boster) for 2 h followed by incubation with avidin–biotin–peroxidase complex (1:200, Wuhan Boster) for 2 h. Finally, the sections were exposed for 0.5—2 min to 0.01% 3,3’-diaminobenzidine (Wuhan Boster). Normal goat serum was used instead of the primary antibody in the control sections. Positive cells were counted in the ischemic hemisphere.

**Statistical Analysis** The data are expressed as mean±standard error (S.E.). Survival curves were constructed according to the Kaplan–Meier method. Differences in survival rates among groups were examined by the log rank test. Others were performed using one-way analysis of variance or the non-parametric Kruskal–Wallis test if the data had a skewed distribution (neurological deficit score) and the Dunnett t-test for neuron density compared with the non-ischemic hemisphere. p<0.05 was considered to be statistically significant.

**RESULTS**

**HJDTet Increased the Survival Rate of Mice** Compared with the ischemia control, HJDTet enhanced the survival rates after ischemia at 400 mg/kg. Although HJDTaq and HJDTet (200, 800 mg/kg) also improved the survival rates after isch-
emia, there were no significant differences between these groups and the ischemia control (Fig. 2).

**HJDTet Reduced the Neurological Deficit Score** The neurological deficit score gradually increased and reached the maximum at 24 h after ischemia; thereafter it decreased, and remained constant until day 35 (Table 1). Treatment with HJDTet at 400 and 800 mg/kg, but not 200 mg/kg, reduced the score from days 14 to 35. HJDTaq also reduced the score from days 14 to 35.

**HJDTet Increased the Performance on the Inclined Board Test** In the inclined board test, the performance of sham-operated mice remained constant over 35 d after operation. After ischemia, the performance decreased from days 1 to 35 and reached a minimum at 24 h (Table 2). Treatment with HJDTet increased the performance at days 14 and 28 at 200 and 400 mg/kg and at days 1 and 14 at 800 mg/kg. The performance in HJDTaq-treated ischemic mice was also increased at day 14.

**HJDTet Reduced the Infarct Volume** At day 35 after ischemia, the ischemic hemisphere was clearly atrophic on gross examination (Fig. 3A) and in the sections stained with toluidine blue (Fig. 3B). The infarct volume at day 35 after ischemia was increased. Treatment with HJDTaq and HJDTet at 400 and 800 mg/kg, but not 200 mg/kg, markedly reduced the infarct volume compared to the ischemia control (Fig. 3C).

**HJDTet Increased the Neuron Density in Hippocampal CA1 Region, Cortex and Striatum** The neuron density significantly decreased at day 35 after ischemia in the hippocampal CA1 region, cortex and striatum of the ischemic hemisphere. Treatment with HJDTaq and HJDTet at 800 mg/kg increased the neuron density in hippocampal CA1 region, cortex and striatum (Fig. 4). Treatment with HJDTet at 400 mg/kg increased the neuron density of cortex only, but not the hippocampal CA1 region and striatum.

**HJDTet Increased the Numbers of CD31-, HIF-1α-, VEGF- and Flk-1-Positive Cells** There were few CD31-, HIF-1α-, VEGF- and Flk-1 positive cells in the sham control. After ischemia, the numbers of CD31- and HIF-1α-positive cells increased. Treatment with HJDTet at 400 and 800 mg/kg further increased the CD31- and HIF-1α-positive cell numbers (Figs. 5A, B). Increased VEGF- and Flk-positive cell numbers were found in the ischemic hemisphere of the ischemia control, but the difference was not significant. Treatment with HJDTaq (4 g/kg) and HJDTet (200, 400, 800 mg/kg) increased the number of VEGF-positive cells over sham control, but only the 800 mg/kg HJDTet treatment increased the number over ischemia control (Fig. 5C). The number of cells expressing Flk-1, a VEGF receptor, was increased after treatment with HJDTaq and HJDTet (400, 800 mg/kg) relative to sham control. Also, the number of Flk-1-positive cells was increased by HJDTaq and HJDTet (800 mg/kg) relative to ischemia control (Fig. 5D).

---

**Fig. 2. Survival Rates of Mice Treated with HJDTaq and HJDTet after Ischemia**

Compared with ischemic mice, those treated with HJDTet at 400 mg/kg had a higher survival rate (p<0.05). Curves were constructed according to the Kaplan–Meier method. Differences of survival rates among groups were determined by the log rank test. HJDTaq, aqueous extract of Huanglian-Jie-Du-Tang; HJDTet, ethanolic extract of Huanglian-Jie-Du-Tang.

**Fig. 3. Effects of HJDTaq and HJDTet on Infarct Volume at Day 35 after Focal Cerebral Ischemia in Mice**

Mice were treated with HJDTet (200, 400, 800 mg/kg) or HJDTaq (4 g/kg) for 21 consecutive days (initial dose at day 7 before ischemia). Data are expressed as mean±S.E. (n=9–27). *p<0.05 or **p<0.01 relative to sham control; ***p<0.01 relative to ischemia control. Isch, ischemia; HJDTaq, aqueous extract of Huanglian-Jie-Du-Tang; HJDTet, ethanolic extract of Huanglian-Jie-Du-Tang. Scale bar in B, 5 mm.
### Table 1. Effects of HJDTaq and HJDTet on Neurological Deficit Score over 35 d after Focal Cerebral Ischemia in Mice

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>0 d</th>
<th>1 d</th>
<th>3 d</th>
<th>7 d</th>
<th>14 d</th>
<th>21 d</th>
<th>28 d</th>
<th>35 d</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>27</td>
<td>0.00±0.00</td>
<td>0.00±0.00</td>
<td>0.00±0.00</td>
<td>0.00±0.00</td>
<td>0.00±0.00</td>
<td>0.00±0.00</td>
<td>0.00±0.00</td>
<td>0.00±0.00</td>
</tr>
<tr>
<td>Ischemia</td>
<td>10</td>
<td>0.00±0.00</td>
<td>1.80±0.25**</td>
<td>1.70±0.26**</td>
<td>1.50±0.27**</td>
<td>1.50±0.27**</td>
<td>1.40±0.22**</td>
<td>1.40±0.22**</td>
<td>1.40±0.22**</td>
</tr>
<tr>
<td>HJDTaq (200 mg/kg)</td>
<td>14</td>
<td>0.00±0.00</td>
<td>1.43±0.14**</td>
<td>1.21±0.11**</td>
<td>1.00±0.10**</td>
<td>0.57±0.17**</td>
<td>0.50±0.23**</td>
<td>0.43±0.17**</td>
<td>0.36±0.17**</td>
</tr>
<tr>
<td>(400 mg/kg)</td>
<td>16</td>
<td>0.00±0.00</td>
<td>1.78±0.22**</td>
<td>1.56±0.24**</td>
<td>1.33±0.24**</td>
<td>1.11±0.31**</td>
<td>1.11±0.31**</td>
<td>1.00±0.24**</td>
<td>1.00±0.24**</td>
</tr>
<tr>
<td>(800 mg/kg)</td>
<td>11</td>
<td>0.00±0.00</td>
<td>1.44±0.16**</td>
<td>1.31±0.15**</td>
<td>0.94±0.19**</td>
<td>0.75±0.21**</td>
<td>0.75±0.23**</td>
<td>0.63±0.22**</td>
<td>0.63±0.22**</td>
</tr>
<tr>
<td>HJDTet (400 mg/kg)</td>
<td>9</td>
<td>0.00±0.00</td>
<td>1.78±0.22**</td>
<td>1.56±0.24**</td>
<td>1.33±0.24**</td>
<td>1.11±0.31**</td>
<td>1.11±0.31**</td>
<td>1.00±0.24**</td>
<td>1.00±0.24**</td>
</tr>
<tr>
<td>(800 mg/kg)</td>
<td>16</td>
<td>0.00±0.00</td>
<td>1.45±0.21**</td>
<td>1.27±0.14**</td>
<td>1.00±0.19**</td>
<td>0.82±0.18**</td>
<td>0.64±0.20**</td>
<td>0.36±0.15**</td>
<td>0.36±0.15**</td>
</tr>
</tbody>
</table>

Mice were treated with HJDTet (200, 400, 800 mg/kg) or HJDTaq (4 g/kg) for 21 consecutive days (initial dose at day 7 before ischemia). Data are expressed as mean±S.E. (n=9—27). **p<0.01 relative to sham control; #p<0.05 or ##p<0.01 relative to ischemia control. HJDTaq, aqueous extract of Huanglian-Jie-Du-Tang; HJDTet, ethanolic extract of Huanglian-Jie-Du-Tang.

### Table 2. Effects of HJDTaq and HJDTet on Performance in the Inclined Board Test over 35 d after Focal Cerebral Ischemia in Mice

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>0 d</th>
<th>1 d</th>
<th>3 d</th>
<th>7 d</th>
<th>14 d</th>
<th>21 d</th>
<th>28 d</th>
<th>35 d</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>27</td>
<td>71.94±0.55</td>
<td>72.43±0.52</td>
<td>73.16±0.71</td>
<td>74.73±0.73</td>
<td>72.93±0.78</td>
<td>71.49±0.94</td>
<td>73.87±0.69</td>
<td>74.49±0.57</td>
</tr>
<tr>
<td>Ischemia</td>
<td>10</td>
<td>71.63±0.91</td>
<td>53.89±3.47**</td>
<td>60.99±3.47**</td>
<td>62.77±3.01**</td>
<td>60.18±3.30**</td>
<td>62.60±2.59**</td>
<td>65.24±2.56**</td>
<td>68.22±2.02**</td>
</tr>
<tr>
<td>HJDTaq (200 mg/kg)</td>
<td>14</td>
<td>73.07±0.94</td>
<td>62.80±2.35**</td>
<td>67.71±2.10</td>
<td>69.61±1.28</td>
<td>71.69±1.71**</td>
<td>71.01±1.31</td>
<td>70.76±1.88</td>
<td>70.54±1.66</td>
</tr>
<tr>
<td>(400 mg/kg)</td>
<td>16</td>
<td>72.58±1.14</td>
<td>59.73±3.29**</td>
<td>64.80±3.66</td>
<td>65.81±4.45*</td>
<td>69.54±3.71**</td>
<td>67.64±4.40</td>
<td>73.69±1.88*</td>
<td>72.47±2.91</td>
</tr>
<tr>
<td>(800 mg/kg)</td>
<td>11</td>
<td>71.89±0.99</td>
<td>62.58±2.20**</td>
<td>65.25±1.83*</td>
<td>67.96±1.74*</td>
<td>69.12±1.52*</td>
<td>68.16±1.56</td>
<td>72.56±2.00*</td>
<td>72.76±1.61</td>
</tr>
</tbody>
</table>

Mice were treated with HJDTet (200, 400, 800 mg/kg) or HJDTaq (4 g/kg) for 21 consecutive days (initial dose at day 7 before ischemia). Data are expressed as mean±S.E. (n=9—27). *p<0.05 or **p<0.01 relative to sham control; $p<0.05 or **p<0.01 relative to ischemia control. HJDTaq, aqueous extract of Huanglian-Jie-Du-Tang; HJDTet, ethanolic extract of Huanglian-Jie-Du-Tang.
DISCUSSION

Here, we confirmed that HJDTet protects mice against chronic brain injury after focal cerebral ischemia. The results showed that HJDTet attenuated neurological dysfunction and reduced infarct volume as well as neuronal degeneration. The effective doses ranged from 400 to 800 mg/kg. Furthermore, we found that HJDTet accelerated the angiogenesis surrounding the ischemic tissue as evidenced by increasing the number of CD31-positive cells, accompanied by increases of HIF-1α, VEGF-, and Flk-1-positive cells.

More than half of the animals in the ischemia control group died within the 35-day observation period, likely due to the large cerebral infarct, the associated edema and intestinal tympanites, as previously reported.25,26) HJDTaq and HJDTet reduced the death rate after ischemia during this period. Especially, HJDTet at 400 mg/kg enhanced the survival rate of mice after ischemia. However the survival rate was conversely reduced at 800 mg/kg HJDTet. The possible toxicity or the induced imbalance between endogenous regulatory mechanisms might relate to the failure in reducing death of ischemic mice after treatment of HJDTet at much larger doses (such as 800 mg/kg).

Our studies showed that HJDTet exerted dose-dependent neuroprotective effects on chronic cerebral ischemia. The effective dose of HJDTet ranged from 400 to 800 mg/kg, which is far lower than that reported for HJDTaq.5—10,12) The lower effective dose of HJDTet indicated a more active prepara-

Fig. 4. Effects of HJDTaq and HJDTet on Neuron Density in Hippocampal CA1 Region, Cortex and Striatum at Day 35 after Focal Cerebral Ischemia in Mice

Data are expressed as mean±S.E. (n=9—27). **p<0.01 relative to non-ischemic hemisphere; *p<0.05 or #p<0.01 relative to ischemia control. Isch, ischemia; HJDTaq, aqueous extract of Huanglian-Jie-Du-Tang; HJDTet, ethanolic extract of Huanglian-Jie-Du-Tang.

Our new findings are that HJDTet modifies the post-ischemic brain remodeling as it accelerates angiogenesis in the boundary zone after 35d. HIF-1 is a well-known complex involved in the intracellular signaling in response to hypoxia and ischemia. HIF-1 is known to play a key role in the development of cancer and angiogenesis.30) It consists of one HIF-1α subunit and one HIF-1β subunit. Oxygen regulates the function, subcellular localization, and level of the HIF-1α units, while HIF-1β is expressed continuously.31) Our results showed increased numbers cells expressing HIF-1α in the boundary of the ischemic region after treatment of HJDTet at much larger doses (such as 800 mg/kg).

Fig. 5. Effects of HJDTaq and HJDTet on Numbers of CD31-, HIF-1α-, VEGF- and Flk-1-Positive Cells

Mice were treated with HJDTet (200, 400, 800 mg/kg) or HJDTaq (4 g/kg) for 21 consecutive days (initial dose at day 7 before ischemia). Data are expressed as mean±S.E. (n=9—27). *p<0.05 or **p<0.01 relative to sham control; #p<0.05 or ##p<0.01 relative to ischemia control. Isch, ischemia; HJDTaq, aqueous extract of Huanglian-Jie-Du-Tang; HJDTet, ethanolic extract of Huanglian-Jie-Du-Tang.
Platelet endothelial cell adhesion molecule-1 (CD31/PECAM-1) is a cell-cell adhesion molecule that is expressed on circulating platelets, on leukocytes, and at the intercellular junctions of vascular endothelial cells, where it mediates the interactions of these cells during the process of transendothelial cell migration, thrombosis, wound healing, and angiogenesis (in cancer, stroke and others).\textsuperscript{32—34} VEGF promotes adult angiogenesis for re-establishment of blood flow following ischemic damage.\textsuperscript{29} Administration of exogenous VEGF following stroke results in reduced neuronal cell death, increased angiogenesis and increased vascular permeability.\textsuperscript{36—38} In hypoxia, the transcription of VEGF is increasingly regulated by HIF-1α, one of the most potent regulators.\textsuperscript{39,40} In conjunction with these findings, our studies showed that HJDTaq and HJDTet increased the expression of HIF-1α and VEGF. We further showed that one of the VEGF receptors, Flk-1, was also increased in hypoxic/ischemic conditions, as previously reported.\textsuperscript{41—43} These data suggest that the angiogenesis effects of HJDTaq and HJDTet may be related to the regulation of VEGF and its receptor.

In conclusion, the results of the present study show that HJDTet ameliorates chronic brain injury after focal cerebral ischemia in mice and leads to angiogenesis in the boundary ischemic region. HJDTet enhances the expression of HIF-1α and its downstream targets, VEGF and Flk-1, ultimately leading to accelerated angiogenesis and ameliorated neurological outcome.

Acknowledgements This study was supported by Grants from the Scientific Foundation of Zhejiang Province Education Department (Y200909752) and the Scientific Foundation in TCM of Zhejiang Province (2011ZA018). The authors would like to thank Dr. I. C. Bruce for critically reading and revising this manuscript.

REFERENCES


